Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). Elelyso (taliglucerase alfa) is the Company's drug product, which is a plant cell expressed recombinant glucocerebrosidase enzyme (GCD) for the treatment of Gaucher disease. The Company's product pipeline includes PRX-102, PRX-106, PRX-110 and PRX-112. PRX-102 (alpha-GAL-A) is a therapeutic protein candidate for the treatment of Fabry disease. PRX-106 is an oral antiTNF product candidate, which is under development as an orally-delivered anti-inflammatory treatment. PRX-110 (AIR DNase) is a plant cell recombinant human Deoxyribonuclease 1 (DNase), under development for the treatment of cystic fibrosis. PRX-112 is an orally administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant GCD enzyme.